Sun, Feb 1, 2015, 12:27 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • afro_bro_bro afro_bro_bro Jul 1, 2014 4:21 PM Flag

    Current Morgan Stanley ANALyst was same negative UBS guy

    This guy moved from UBS and now is at Morgan Stanley. Here is his negative report from UBS ... 2 years ago:

    "While we believe T-DM1, ImmunoGen's antibody drug conjugate of Herceptin with partner Roche is a sig. step forward in the treatment of HER2+ breast cancer, we believe the Street is overestimating the peak and time-to-peak for T-DM1 sales," analyst Matthew Harrison states. "Based on our survey, we see little off-label Rxs into the adjuvant setting (~70-80% of revs) until 2018 when Roche has data. Further, without significant adjuvant sales until 2018, the stock is implying 60% average penet ration for T-DM1 over the 12 year royalty term versus our modeled ~20% average penetration."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.63+1.4300(+23.06%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.